Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study - Quiz - MDSpire

Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study

  • By

  • Matthias Augustin

  • Paul-Gunther Sator

  • Ralph von Kiedrowski

  • Dimitris Rigopoulos

  • Marco Romanelli

  • Pierre-Dominique Ghislain

  • Tiago Torres

  • Dimitrios Ioannides

  • Cynthia Vizcaya

  • Andreas Clemens

  • Weibin Bao

  • Christelle C. Pieterse

  • Barbara Schulz

  • Piotr Jagiello

  • Curdin Conrad

  • April 2, 2026

  • 0 min

Share

Original Source(s)

Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study

  • by Matthias Augustin, Paul-Gunther Sator, Ralph von Kiedrowski, Dimitris Rigopoulos, Marco Romanelli, Pierre-Dominique Ghislain, Tiago Torres, Dimitrios Ioannides, Cynthia Vizcaya, Andreas Clemens, Weibin Bao, Christelle C. Pieterse, Barbara Schulz, Piotr Jagiello, Curdin Conrad

  • April 2, 2026

Related Content

Integrated systems toxicology identifies TCDD-responsive targets linked to immune dysregulation and treatment response in psoriasis

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

Development and Validation of the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO®)